Women approaching menopause drive GLP-1 boom
Why it matters: This is another cultural moment when women, especially those approaching menopause, are paying more for their well-being.
Between the lines: GLP-1 drugs like Ozempic and Mounjaro are usually covered by insurance when used to treat Type 2 diabetes — but many doctors also prescribe them off-label for overweight and obesity, which often isn't covered.
By the numbers: Women have been prescribed GLP-1 drugs at higher rates than men since 2021, according to 2024 data from FAIR Health.
The fine print: The data reflects insured adults who received medical care nationally, but doesn't include people buying non-FDA-approved versions of the drugs from compounding pharmacies.
Zoom in: 18.6% of women prescribed GLP-1 drugs received them for weight loss (and not diabetes) — double the rate of men, at 9.3% — according to FAIR Health.
Women between 40 and 64 have been the top recipients of GLP-1 prescriptions since 2019. For men, the top users in most years have been seniors.
What we're hearing:"In my experience, thus far, it's been entirely women" — many of them approaching menopause — who ask to be on GLP-1 drugs to lose weight, says family physician Beth Oller, who practices in rural Kansas.
At a certain age, "the things you used to do for weight loss aren't cutting it anymore," says Oller, who's 45 and tells Axios she has firsthand experience with this.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
FDA vaccine official restricted COVID vaccine approvals against the advice of agency staff
WASHINGTON (AP) — The government's top vaccine official working under Health Secretary Robert F. Kennedy Jr. recently restricted the approval of two COVID-19 vaccines, disregarding recommendations from government scientists, according to federal documents released Wednesday. The new memos from the Food and Drug Administration show how the agency's vaccine chief, Dr. Vinay Prasad, personally intervened to place restrictions on COVID shots from vaccine makers Novavax and Moderna. Both vaccines were approved by the FDA in May after months of analysis by rank-and-file FDA reviewers. But internal correspondence show Prasad disagreed with staffers who planned to approve the shots for everyone 12 and older, similar to previous COVID vaccines. The scientists had concluded the benefit from the vaccines and the risk of COVID-19 outweighed the risk of possible side effects, which are rare. Instead Prasad decided the shots should be limited to those who face special risks from the virus— seniors or children and adults with underlying medical issues. Prasad explained that the COVID vaccine benefits must be reconsidered in light of falling rates of death and hospitalization and the possibility for vaccine side effects. It's the latest in a series of vaccine restrictions imposed by officials working under Kennedy, who has long questioned the benefits of vaccines. 'Even rare vaccination related harms both known and unknown now have higher chance of outweighing potential benefits' Prasad wrote in a five-page memo explaining his decision. COVID-19 remains a public health threat, resulting in 32,000 to 51,000 U.S. deaths and more than 250,000 hospitalizations since last fall, according to the Centers for Disease Control and Prevention. Most at risk for hospitalization are seniors and children under 2 — especially infants under 6 months. Top FDA leaders are typically not involved in the review of individual products. Officials like Prasad can overrule staffers, but such cases are rare and often controversial. News of the FDA documents was first reported by the New York Times. Prasad was hired to lead the FDA's vaccine center in May, after the previous director, Dr. Peter Marks, was forced to resign over disagreements with Kennedy. An academic researcher specializing in cancer therapies, Prasad came to prominence during the pandemic for criticizing public health measures, including the FDA's approval of COVID boosters for healthy adults and children. Since arriving at the agency he has worked with FDA Commissioner Mark Makary on new guidelines that will limit approvals of future COVID boosters to higher-risk Americans, mainly seniors and those with medical conditions like asthma and obesity. Those limits match the terms FDA recently approved for Novavax's shot, Nuvaxovid and Moderna's mNexspike. Novavax's vaccine is the only protein-based coronavirus vaccine available in the U.S. Moderna's vaccine is an updated, lower-dose version of its existing mRNA-based vaccine. The review team for the Novavax vaccine pointed to data from a study in 30,000 adults, concluding that 'the risk-benefit assessment for this vaccine technology remains favorable.' FDA staff reached a similar conclusion for the Moderna vaccine, deeming it similar in safety and effectiveness to the company's original shot. Last week, the FDA finalized new warning labeling about the risk of myocarditis, a rare form of heart inflammation, on shots from Moderna and Pfizer, the other maker of an mRNA-based shot for COVID. In his 'override memo,' reversing FDA staff's decision on the Moderna shot, Prasad pointed to the ongoing risk of myocarditis and questions about its frequency. The agency ordered Moderna to conduct further studies of the risk as a condition for the approving its updated shot. A spokesman for the administration said Prasad 'has raised serious concerns' about the issue. 'We will not ignore these risks and will ensure that the gold standard of science is used for any decisions,' said Andrew Nixon, in an emailed statement. Outside researchers have noted that cases of the heart condition tend to resolve quickly and are less severe than those associated with COVID infection itself, which can also cause myocarditis. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Epoch Times
4 hours ago
- Epoch Times
Beating Cancer With the Heart: One Professor's Mindset Helped Him Stay Healthy for 15 Years
A 7.5-inch tumor, lung metastasis, and multiple rounds of treatment—Han Bo-Cheng, an honorary professor at Taipei Medical University, overcame all odds to defeat liver cancer. Fifteen years later, he remains cancer-free and attributes his recovery not only to medicine but to one powerful force: emotional healing. His story offers hope and insight for those facing cancer or any life-altering crisis. Healing from the Inside Out: A Cancer Survivor's Journey When you are diagnosed with cancer, how you face the illness and navigate treatment becomes a major concern for both you and your loved ones. For Han, the turning point wasn't just medical—it was emotional. In 2008, Han was diagnosed with liver cancer and discovered a massive 7.5-inch, 4.4-pound tumor. After undergoing surgery to remove two-thirds of his liver, the cancer later spread to his lungs. He endured 25 chemotherapy sessions, 12 rounds of radiation, and targeted drug therapy. When the cancer recurred three years later, he required another surgery. Since then, Han has remained cancer-free. Not only has he regained his health, but he also appears younger than his age—something he credits to a complete transformation in mindset. Emotional Healing: The Missing Piece in Cancer Recovery Han believes a crucial part of healing lies in addressing emotions. 'I am the root of all problems, and love is the answer to all of them,' Han said in an interview with NTDTV's 'Health 1+1' program—a central realization during his recovery.
Associated Press
4 hours ago
- Associated Press
UTILITY Therapeutics Announces Acquisition by Alembic Pharmaceuticals Inc.
LONDON, UK / ACCESS Newswire / July 3, 2025 / UTILITY therapeutics Ltd. (UTILITY), a biotechnology company focused on the development of PIVYA (pivmecillinam 185 mg tablets), a penicillin class antibacterial approved by the U.S. Food and Drug Administration (FDA) for the treatment of uncomplicated urinary tract infection (uUTI), today announced that it has been acquired by Alembic Pharmaceuticals, Inc. (Alembic). PIVYA marked the first antibiotic in approximately 20 years to earn FDA approval for uUTI, a common bacterial infection that afflicts millions of women annually. The FDA approved PIVYA in April 2024 for use in female patients 18 years of age and older with uUTI caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus. PIVYA has a unique mechanism of action that targets the cell wall of gram-negative bacteria. Additional U.S. prescribing information about PIVYA can be found at 'We are thrilled that Alembic Pharmaceuticals understands the clinical and commercial value of PIVYA and will bring this proven treatment to female patients in need across the U.S.,' said Tom Hadley, President and CEO of UTILITY therapeutics. 'With current therapies failing and the armament of uUTI antibiotics perilously thin, PIVYA provides U.S. clinicians with a new and effective treatment option that has a long safety record. We are grateful for the support of our Board of Directors and investors, including the AMR Action Fund, whose collective support was instrumental in helping us obtain FDA approval for PIVYA.' The UTILITY therapeutics Ltd. Board of Directors and Observers includes: 'The acquisition of UTILITY and the commercialization of PIVYA are important steps in Alembic's strategic goal to provide branded pharmaceutical products to the U.S. healthcare market,' said Craig Salmon, President of Alembic Pharmaceuticals, Inc. 'PIVYA will further enhance Alembic's ability to build long-term value by combining global research, regulatory, and manufacturing strengths with a sharpened focus on specialty segments. Alembic plans to make PIVYA available in the U.S. in the 4th quarter of 2025.' 'I am excited to see Alembic drive the commercialization of PIVYA, which is uniquely positioned to help millions of American women with urinary tract infections,' said Dr. Morten Sommer, Professor of microbiology at the Technical University of Denmark, and co-founder and board member of UTILITY therapeutics. 'With a novel mechanism of action, not previously deployed in the U.S., PIVYA can become a cornerstone of the treatment of urinary tract infections based on its first-line positioning in the Infectious Disease Society of America treatment guidelines. On behalf of the co-founders, investors, and Board of Directors, we are excited that PIVYA will help address the societal impact of the uUTI disease burden in women.' About PIVYA (pivmecillinam oral tablets 185mg) PIVYA, an oral prodrug of mecillinam, is a penicillin class antibacterial indicated for the treatment of female patients 18 years of age and older with uncomplicated urinary tract infections (uUTI) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus. Mecillinam demonstrated in vitro activity against Enterobacterales in the presence of some beta-lactamases and extended-spectrum beta-lactamases (ESBL) of the following groups: CTX-M, SHV, TEM, AmpC. The inhibitory action of mecillinam on PBP-2 results in low cross-resistance with certain beta-lactams. The frequency of resistance to mecillinam in E. coli range from 8×10-8 to 2×10-5 when exposed to 32-256 times MIC. PIVYA has been proven safe and effective in three clinical trials with the most common Adverse Reactions Occurring in ≥1% of Patients Receiving PIVYA (Adjusted for Study Size); Nausea (4.3%), Diarrhea (2.1%), Vulvovaginal candidiasis (1.8%), Genital pruritus (1.8%), and Headache (1.4%). PIVYA demonstrated strong response in three controlled clinical trials comparing different PIVYA dosing regimens to placebo (Trial 1), to another oral antibacterial drug (Trial 2), or to ibuprofen (Trial 4) evaluated the efficacy of pivmecillinam for the treatment of uUTI. Efficacy was assessed in the Microbiological Intent-to-Treat (micro-ITT) population which included all randomized subjects with a positive baseline urine culture defined as ≥105 colony-forming-units (CFU)/mL of a uropathogen where CFU count was available and no more than 2 species of microorganisms, regardless of colony count, and no baseline pathogen was non-susceptible to the active comparator. The composite response rates (composite endpoint of clinical cure and microbiological response), as well as clinical cure and microbiological response rates of the recommended 185 mg three times daily dosing regimen. Composite Response Rates (Clinical Cure and Microbiological Response) at TOC in the uUTI trials (Micro ITT Population) Clinical Cure Rates (Micro-ITT Population) Microbiological Response Rates (Micro-ITT Population) Contraindications Warnings and precautions About UTILITY therapeutics Ltd. UTILITY has exclusive U.S. commercial rights to two European-approved antibiotics, pivmecillinam and mecillinam, for the treatment of urinary tract infections (UTI). Pivmecillinam is an oral prodrug of mecillinam that has been approved by the FDA for the treatment of women with uncomplicated urinary tract infections. PIVYA has a unique mechanism of action for infections caused by Gram-negative bacteria, including extended-spectrum beta-lactamases. Mecillinam, an intravenous (IV) formulation, may be developed as a first-line therapy for complicated UTI (cUTI) in the hospital setting. For more information, contact David Cobb, Alembic Pharmaceuticals [email protected] 908-552-583 SOURCE: Utility Therapeutics Ltd. press release
